EQ

Equillium, Inc. (NASDAQ:EQ) is a clinical-stage biotechnology company founded in 2017 and headquartered in La Jolla, California. The company was originally incorporated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium in May 2017. Equillium went public in October 2018 and focuses on developing treatments for severe autoimmune and inflammatory disorders that currently have limited treatment options. The company is primarily engaged in advancing its lead drug candidate through clinical trials while also developing a pipeline of additional therapeutic candidates.